San Francisco December 7, 2023 – Cothera Bioscience, a clinical stage biotech company developing therapeutics for previously undruggable oncology targets with high unmet medical needs, today announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation to PC-002, a first-in-class deubiquitinase (DUB) inhibitor that induces myc...
Cothera Announces Dosing of First Patient in Phase 2 Clinical Trial to Test Its DUB Inhibitor PC-002 for the Treatment of High-Grade B-cell Lymphoma
San Francisco, December 19, 2022--Cothera Bioscience today announced that it has dosed the first patient with PC-002, a first-in-class deubiquitinase (DUB) inhibitor, in a global multi-center phase 2 clinical trial for the treatment of high-grade B-cell lymphoma with Myc rearrangement (NCT05263583). This is a single-arm, single-agent proof-of-concept trial designed to...
Cothera Acquires Exclusive Worldwide Rights to Zotiraciclib, a Novel Oral Multi-kinase Inhibitor from Adastra Pharmaceuticals
Beijing, San Francisco, September 7, 2021--Cothera Bioscience today announced that it has reached an agreement to acquire exclusive worldwide rights to zotiraciclib (ZTR/TG02) from Adastra Pharmaceuticals, Inc.Dr. Alex Wu, Co-founder and CEO of Cothera Bioscience, said: "This is a very important strategic deal for Cothera as it broadens our pipeline...
